ASX:AHZ

ADMEDUS LTD

Scott Power

The healthcare sector has been very strong this year, and here we touch on eight players within it. There have also been a couple of laggards in that space too, and they are the IVF players. So we've been sitting with neutral recommendations on the space the last two years.... Show More

A first strike at Cover-more Group and results for BlueScope Steel and Treasury Wine Estates (with Wesfarmers results later today). In today's note I also take a look at the poll versus show of hands as a method of voting, with three AGM examples to show the benefits of a... Show More

Stuart Roberts

Ian Frazer, of the University of Queensland, was Australian of the Year in 2006 because his research created Gardasil, the cervical cancer vaccine. Like all good Professors, Frazer hasn't stopped generating Next Big Thing ideas, and one of them is DNA vaccines to prompt a patient's own immune system to... Show More

Scott Power

“The Morgans Healthcare team has today released its top 5 emerging healthcare names with some near term milestones. Companies that we’re looking at that we think over the next 1-2 months will produce some catalysts that if positive will drive the share prices.” For the list of 5 stocks and... Show More

Scott Power

Admedus has had an interesting couple of months including the completion of a successful capital raising. The company has three business divisions, however, in this interview we focus specifically on the tissue regenerative medicines business. The lead product in this business is called Cardiocell and we ask Lee to share... Show More

Scott Power

Admedus (AHZ, Add, Price Target A$0.20) AHZ posted a solid 3QFY15 result with revenue up 47% to A$2.4m. We estimate the key CardiolCel® sales were approximately A$800,000 with now over 60 centres in US and Europe using the device. Following the recent capital raising, AHZ is well funded and a... Show More